• Version
• Download 10041
• File Size 522.67 KB
• File Count 2
• Create Date 30 June 2020
• Last Updated 28 July 2020

Statement on the use of Dexamethasone for severely ill COVID-19 Patients

This statement aims to provide guidance and recommendation to African Union Member States.

Africa Centers for Disease Control and Prevention (Africa CDC) is aware of the media releases of the preliminary results of a large randomized clinical trial conducted in the United Kingdom, which included dexamethasone, a corticosteroid, as one of the drugs used for the treatment of COVID-19 patients. The investigators reported that administration of oral or injectable dexamethasone resulted in about one-third reduction in mortality among COVID-19 patientsi that required mechanical ventilation and about one-fifth for patients requiring oxygen.

Attached Files